Insider Buying: Embecta (NASDAQ:EMBC) CFO Buys $93,400.00 in Stock

Embecta Corp. (NASDAQ:EMBC) CFO Jacob Elguicze purchased 20,000 shares of the business’s stock in a transaction on Wednesday, August 12th. The shares were bought at an average cost of $4.67 per share, for a total transaction of $93,400.00. Following the completion of the transaction, the chief financial officer directly owned 309,139 shares in the company, valued at $1,443,679.13. This trade represents a 6.92% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link.

Embecta Stock Performance

NASDAQ EMBC opened at $5.10 on Friday. The firm has a market capitalization of $288.97 million, a P/E ratio of 3.45 and a beta of 0.81. The stock has a 50-day simple moving average of $3.50 and a two-hundred day simple moving average of $6.41. Embecta Corp. has a fifty-two week low of $2.77 and a fifty-two week high of $15.55.

Embecta (NASDAQ:EMBC) last issued its earnings results on Friday, August 7th. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.29. The firm had revenue of $271.70 million for the quarter, compared to the consensus estimate of $254.53 million. Embecta had a negative return on equity of 19.25% and a net margin of 8.59%.The company’s revenue was down 8.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.12 earnings per share. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. As a group, analysts forecast that Embecta Corp. will post 1.84 earnings per share for the current year.

Embecta Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Thursday, August 27th will be issued a $0.01 dividend. The ex-dividend date of this dividend is Thursday, August 27th. This represents a $0.04 dividend on an annualized basis and a yield of 0.8%. Embecta’s payout ratio is presently 2.70%.

Hedge Funds Weigh In On Embecta

Hedge funds have recently bought and sold shares of the business. Brooklyn Investment Group grew its holdings in Embecta by 5.9% in the fourth quarter. Brooklyn Investment Group now owns 19,736 shares of the company’s stock valued at $234,000 after purchasing an additional 1,098 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of Embecta by 5.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,589 shares of the company’s stock worth $209,000 after buying an additional 1,110 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Embecta by 2.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock worth $629,000 after buying an additional 1,159 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Embecta by 1.0% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,271 shares of the company’s stock valued at $1,785,000 after buying an additional 1,520 shares in the last quarter. Finally, A&I Financial Services LLC lifted its position in shares of Embecta by 2.5% during the 4th quarter. A&I Financial Services LLC now owns 63,542 shares of the company’s stock valued at $755,000 after buying an additional 1,556 shares in the last quarter. Hedge funds and other institutional investors own 93.83% of the company’s stock.

Analyst Upgrades and Downgrades

EMBC has been the topic of a number of analyst reports. Mizuho dropped their price objective on shares of Embecta from $12.00 to $5.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Weiss Ratings downgraded shares of Embecta from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, August 3rd. Zacks Research upgraded shares of Embecta from a “strong sell” rating to a “hold” rating in a research report on Friday, July 17th. BTIG Research cut shares of Embecta from a “buy” rating to a “neutral” rating in a report on Tuesday, May 5th. Finally, Bank of America decreased their price objective on shares of Embecta from $11.00 to $3.00 and set an “underperform” rating for the company in a research report on Monday, May 18th. Three research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus target price of $11.00.

Key Embecta News

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: CEO Devdatt Kurdikar, CFO Jacob Elguicze and director Jeffrey Z. Mann collectively purchased 70,000 shares worth approximately $334,200 on August 12. The insider buying could signal that management and the director believe Embecta’s shares are undervalued after their steep decline. SEC insider transaction filing
• Neutral Sentiment: Embecta also disclosed a quarterly dividend of $0.01 per share, or $0.04 annualized, with a yield of roughly 0.8%. The modest payout is unlikely to be a major near-term stock catalyst but may appeal to income-focused investors. Embecta dividend and insider trading report
• Neutral Sentiment: Multiple law firms, including Hagens Berman, Bronstein Gewirtz & Grossman, Kaplan Fox, Faruqi & Faruqi and Rosen, reminded investors that August 17 is the deadline to seek lead-plaintiff status. The notices target investors who purchased EMBC securities between November 25, 2025, and May 4, 2026, and mostly repeat previously reported information. Hagens Berman class action deadline notice
• Negative Sentiment: The underlying securities class action alleges that Embecta and certain executives misrepresented the commercial stability of its insulin pen-needle business and issued misleading fiscal 2026 guidance. If the claims gain traction, the company could face legal expenses, reputational damage and further questions about management credibility. The allegations have not been proven in court. Hagens Berman lawsuit alert

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.